ReviewBritish journal of clinical pharmacology1998
Therapeutic drug monitoring: antiarrhythmic drugs.
Review in British journal of clinical pharmacology, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 114 citations in OpenAlex.
- The use of the S-Caine patch is safe and feasible in children younger than three: a nonrandomised clinical trial.European journal of pediatrics · 2026Trial
- Development of an optimal lidocaine infusion strategy for neonatal seizures.European journal of pediatrics · 2006Trial
- Treatment of ventricular arrhythmias with oral sotalol in four horses.Journal of veterinary internal medicine · 2026Article
- Targeted Heart Rate Control with Landiolol in Hemodynamically Unstable, Non-Surgical Intensive Care Unit Patients: A Comparative Study.Medicina (Kaunas, Lithuania) · 2025Article
- Transcutaneous electrocardioversion for treatment of atrial fibrillation and congestive heart failure in a Nubian wether.The Canadian veterinary journal = La revue veterinaire canadienne · 2025Article
- Acute and Sub-Chronic Intraperitoneal Toxicity Studies of thePharmaceutics · 2023Article
- Electrochemically driven optical and SERS immunosensor for the detection of a therapeutic cardiac drug.RSC advances · 2022Article
- Effects of 1α,25-Dihydroxyvitamin DPharmaceutics · 2021Article
- Iatrogenic hypertension: a bioinformatic analysis.The pharmacogenomics journal · 2019Article
- Physiologically-Based Pharmacokinetic Modeling for Drug-Drug Interactions of Procainamide andPharmaceutics · 2019Article
- Article
- Effect of sotalol on heart rate, QT interval, and atrial fibrillation cycle length in horses with atrial fibrillation.Journal of veterinary internal medicine · 2018Article
- Application of a systems pharmacology model for translational prediction of hERG-mediated QTc prolongation.Pharmacology research & perspectives · 2016Article
- Sodium channel-inhibiting drugs and survival of breast, colon and prostate cancer: a population-based study.Scientific reports · 2015Article
- The lack of effect of sotalol in short QT syndrome patients carrying the T618I mutation in theHeartRhythm case reports · 2015Article
- Clinical pharmacokinetics of drugs in patients with heart failure: an update (part 2, drugs administered orally).Clinical pharmacokinetics · 2014Review
- Adverse drug reactions in elderly subjects hospitalized in a specialized dementia management unit.Drugs & aging · 2014Article
- Antiarrhythmic therapy in atrial fibrillation: indications, guidelines, and safety.Texas Heart Institute journal · 2012Review
- Is antiarrhythmic treatment in the elderly different? a review of the specific changes.Drugs & aging · 2011Review
- Modeling cardiac uptake and negative inotropic response of verapamil in rat heart: effect of amiodarone.Pharmaceutical research · 2007Article
Corrections and comments
- Commented on by
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antiarrhythmic agents are traditionally classified according to Vaughan Williams into four classes of action. Class I antiarrhythmic agents include most of the drugs traditionally thought of as antiarrhythmics, and have as a common action, blockade of the fast-inward sodium channel on myocardium. These agents have a very significant toxicity, and while they are being used less, therapeutic drug monitoring (TDM) does significantly increase the safety with which they can be administered. Class II agents are antisympathetic drugs, particularly the beta-adrenoceptor blockers. These are generally safe agents which do not normally require TDM. Class III antiarrhythmic agents include sotalol and amiodarone. TDM can be useful in the case of amiodarone to monitor compliance and toxicity but is generally of little value for sotalol. Class IV antiarrhythmic drugs are the calcium channel blockers verapamil and diltiazem. These are normally monitored by haemodynamic effects, rather than using TDM. Other agents which do not fall neatly into the Vaughan Williams classification include digoxin and perhexiline. TDM is very useful for monitoring the administration (and particularly the safety) of both of these agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.